Swedish-US collaboration to fight inflammatory diseases

Swedish based Athera Biotechnologies AB and the American company Dyax Corp. will enter into a collaboration to discover and to develop therapeutic products for the prevention or treatment of cardiovascular inflammatory diseases.

“We are very pleased to be working with Athera,” commented Clive Wood, EVP, Discovery Research and CSO of Dyax Corp.  “Through their innovative research from the Karolinska Institutet, we believe Athera has identified an exciting potential opportunity for therapeutic antibody treatment of cardiovascular inflammation.”

“The strength of Dyax’s phage display technology, screening capabilities and expertise in drug discovery make them an excellent partner to advance our cardiovascular research program," said Carina Schmidt, CEO of Athera.